Therefore, with the expectation of providing a new insight for BC treatment, we enrolled 100 BC patients receiving neoadjuvant chemotherapy and conducted cell experiments and in vivo experiments to discuss the regulatory roles of CCAT2 in BC cell drug sensitivity to 5‐Fu via the mTOR pathway. The gene discussed is MTOR; the disease is breast cancer.